Skip to main content

Stankovich Thomas's Form 4 filing

Vyome Holdings, Inc (HIND) · filed Jul 6, 2023

Accession no.
0001235802-23-000075
Filed
Jul 6, 2023
Trade date
Mar 31-Jun 30, 2023
Filing delay
97 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market purchases total $26.9K. Open-market sales total $746.14. It was filed 97 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Stankovich ThomasCIK 0001181166Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 31, 2023Common Stock, $0.001 par value per shareSSaleDisposed−109$2.60−$283.45,982Direct
Apr 30, 2023Common Stock, $0.001 par value per shareSSaleDisposed−96$2.36−$226.565,886Direct
May 31, 2023Common Stock, $0.001 par value per shareSSaleDisposed−98$2.41−$236.185,788Direct
Jun 30, 2023Common Stock, $0.001 par value per sharePPurchaseAcquired+17,702$1.52F2+$26,907.0423,490Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)